Aerocrine appoints pulmonologist Paul Dorinsky, M.D., as medical director, North America

Aerocrine appoints pulmonologist Paul Dorinsky, M.D., as medical director, North
America

SOLNA, Sweden – 17 January, 2012 – Aerocrine AB (OMX Nordic Exchange: AERO)
today announced that they have strengthened their medical team by adding former
Teva R&D VP, Dr. Paul Dorinsky.  Paul joins Aerocrine as medical director, North
America.

Paul is board certified in pulmonary and critical care medicine. He spent 15
years on faculty at The Ohio State University College of Medicine before joining
the industry in 1997. Most recently, Dr. Dorinsky served as vice president,
global respiratory R&D, at Teva Pharmaceuticals. He has also worked at
Boehringer Ingelheim and GlaxoSmithKline, where he spent 10 years in various
leadership positions in respiratory clinical development and medical affairs.

Based in the U.S., Dr. Dorinsky will have the responsibility of leading clinical
development and medical affairs for North America. He will report directly to
Kathy Rickard, M.D., chief medical officer.

“As a nationally recognized expert in pulmonary disease, Dr. Dorinsky brings
extensive clinical knowledge in the areas of asthma management and airway
inflammation,” says Dr. Rickard. “His deep experience in clinical trial design
and commercialization for respiratory products is invaluable, and I am pleased
to welcome Dr. Dorinsky to Aerocrine’s medical team.”

Asthma is a chronic inflammatory disease of the airways that affects more than
300 million people worldwide, many of whom are children. FeNO is a marker of the
underlying airway inflammation associated with asthma, and Aerocrine has
developed a method to quickly measure this inflammation. Using NIOX MINO®, a
simple, quantitative and cost-effective test, physicians can obtain information
about the patient’s airway inflammation within two minutes.

For more information, contact:

Kathy Hodgdon, director of sales & marketing Aerocrine Inc., telephone +1 (314)
566 8546

Chip Neff, president Aerocrine Inc., telephone+1 (919) 696 4267